Huiyuan Zhu1,2, Shaochun Yan3, Jingshuo Wu1, Zhong Zhang1, Xiaolin Li1, Zheng Liu1, Xing Ma1, Lina Zhou1, Lin Zhang4, Mingming Feng1, Yiwei Geng1, Aixin Zhang1, Sabina Janciauskiene5, Aiguo Xu2. 1. Department of Pulmonary and Critical Care Medicine, Zhengzhou Second People's Hospital, Zhengzhou Affiliated Hospital of Jinan University, Zhengzhou 450006, China. 2. Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. 3. Department of Cell Biology, School of Basic and Forensic Medicine, Baotou Medical College, Baotou 014040, China. 4. Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. 5. Department of Respiratory Medicine, German Center for Lung Research, Hannover Medical School, Hannover 30625, Germany.
Abstract
BACKGROUND: Previous studies have shown that macrophage migration inhibitory factor (MIF) is involved in the pathogenesis of asthma. This study aimed to investigate whether serum MIF reflects a therapeutic response in allergic asthma. METHODS: We enrolled 30 asthmatic patients with mild-to-moderate exacerbations and 20 healthy controls, analyzing the parameter levels of serum MIF, serum total immunoglobulin E (tIgE), peripheral blood eosinophil percentage (EOS%), and fractional exhaled nitric oxide (FeNO). Lung function indices were used to identify disease severity and therapeutic response. RESULTS: Our study showed that all measured parameters in patients were at higher levels than those of controls. After one week of treatment, most parameter levels decreased significantly except for serum tIgE. Furthermore, we found that serum MIF positively correlated with EOS% as well as FeNO, but negatively correlated with lung function indices. Receiver operator characteristic (ROC) curve analysis indicated that among the parameters, serum MIF exhibited a higher capacity to evaluate therapeutic response. The area under the curve (AUC) of MIF was 0.931, with a sensitivity of 0.967 and a specificity of 0.800. CONCLUSIONS: Our results suggested that serum MIF may serve as a potential biomarker for evaluating therapeutic response in allergic asthma with mild-to-moderate exacerbations.
BACKGROUND: Previous studies have shown that macrophage migration inhibitory factor (MIF) is involved in the pathogenesis of asthma. This study aimed to investigate whether serum MIF reflects a therapeutic response in allergic asthma. METHODS: We enrolled 30 asthmatic patients with mild-to-moderate exacerbations and 20 healthy controls, analyzing the parameter levels of serum MIF, serum total immunoglobulin E (tIgE), peripheral blood eosinophil percentage (EOS%), and fractional exhaled nitric oxide (FeNO). Lung function indices were used to identify disease severity and therapeutic response. RESULTS: Our study showed that all measured parameters in patients were at higher levels than those of controls. After one week of treatment, most parameter levels decreased significantly except for serum tIgE. Furthermore, we found that serum MIF positively correlated with EOS% as well as FeNO, but negatively correlated with lung function indices. Receiver operator characteristic (ROC) curve analysis indicated that among the parameters, serum MIF exhibited a higher capacity to evaluate therapeutic response. The area under the curve (AUC) of MIF was 0.931, with a sensitivity of 0.967 and a specificity of 0.800. CONCLUSIONS: Our results suggested that serum MIF may serve as a potential biomarker for evaluating therapeutic response in allergic asthma with mild-to-moderate exacerbations.
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: Bing Wang; Xiaozhu Huang; Paul J Wolters; Jiusong Sun; Shiro Kitamoto; Min Yang; Richard Riese; Lin Leng; Harold A Chapman; Patricia W Finn; John R David; Richard Bucala; Guo-Ping Shi Journal: J Immunol Date: 2006-11-01 Impact factor: 5.422
Authors: M Kobayashi; Y Nasuhara; A Kamachi; Y Tanino; T Betsuyaku; E Yamaguchi; J Nishihira; M Nishimura Journal: Eur Respir J Date: 2006-02-02 Impact factor: 16.671